The Food and Drug Administration on Tuesday approved Johnson & Johnson’s nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow. 

tag:reuters.com,2025:binary_RC2FACAMPPJR-BASEIMAGE

Reuters

United Kingdom

FDA approves standalone use of J&J's ketamine-derived depression treatment

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.

Ad Fontes Media

All Sides

Media Bias/Fact Check

The Woodbridge Company

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.

Warner Bros. Discovery

Atlanta

Fulton County

Georgia

United States

FDA approves standalone use of J&J’s ketamine-derived depression treatment

Johnson & Johnson medication Spravato, a ketamine-based nasal spray, was approved Tuesday by the Food and Drug Administration for use as a sole treatment for depression.

Washington Times

The Washington Times LLC

FDA approves ketamine-derived nasal spray to fight depression

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder.

CNBC

Roberts family

FDA approves Johnson & Johnson’s nasal spray for depression as standalone treatment

On Tuesday, the FDA approved Johnson & Johnson’s (NYSE:JNJ) supplemental New Drug Application for Spravato (esketamine) CIII nasal spray. The approval makes the treatment the first and only monotherapy for adults living with major depressive disorder (MDD) who have had an inadequate response to at least two oral antidepressants. An estimated 21 million adults in the U.S. live with the disease. About one-third of adults will not respond to oral a…

Benzinga

New York

FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression - Johnson & Johnson (NYSE:JNJ)

The drug was previously approved in combination with antidepressants

The Straits Times

Singapore Press Holdings

Singapore

US FDA approves standalone use of J&J’s ketamine-derived depression treatment

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved in 2019 to treat severe depression.

National Public Radio, Inc

Washington

District of Columbia

FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)

The U.S. Drug Regulatory Agency (FDA) approved Johnson & Johnson's drug Spravato, a nasal spray whose active ingredient is esketamine, as monotherapy treatment for severe depression, this Tuesday.Sketamine first entered the U.S. market in 2019, when the FDA gave the green light to the same drug for use combined with oral antidepressants, and it was a milestone, as it was the first new method approved against depression in 25 years.

La agencia reguladora de fármacos de Estados Unidos (FDA) ha aprobado este martes el fármaco Spravato de Johnson & Johnson, un spray nasal cuyo ingrediente activo es la esketamina, como tratamiento monoterapia para la depresión grave.La esketamina entró por primera vez en el mercado estadounidense en 2019, cuando la FDA dio luz verde a este mismo fármaco para su uso combinado con antidepresivos orales, y fue un hito, ya que era el primer método …

EE UU aprueba un spray nasal como tratamiento único contra la depresión grave

www.larazon.es

Spain

U.S. approves nasal spray as a single treatment for severe depression

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder, or MDD, in adults.

News World Communications

FDA approves Spravato, first monotherapy nasal spray to treat depression

Spravato, the nasal spray from Janssen Pharmaceutica (a subsidiary of Johnson & Johnson), is now allowed to be sold in the United States as a stand-alone treatment for depression. The spray contains esketamine, related to the anesthetic and drug ketamine, and is only administered under medical supervision if other treatments for depression appear to be ineffective.

Spravato, de neusspray van Janssen Pharmaceutica (dochter van Johnson & Johnson), mag in de Verenigde Staten voortaan verkocht worden als alleenstaande behandeling tegen depressie. De spray bevat esketamine, verwant aan het verdovingsmiddel en drug ketamine, en wordt enkel toegediend onder medisch toezicht als andere behandelingen tegen depressie niet blijken te helpen.

FDA approves Johnson & Johnson’s nasal spray for depression as standalone treatment

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics